News
Canadian fertility clinic secures CAD$20m to “revolutionise” reproductive healthcare
Pollin Fertility will become the first company in Canada to give patients full control of their fertility journey
Toronto-based fertility clinic Pollin Fertility has raised CAD$20m in funding to “revolutionise” reproductive healthcare in Canada.
Led by fertility physician and medical director Dr Kim Gardedian, the clinic aims to transform fertility care in Canada and achieve higher success rates in the industry.
Using engineering technology, artificial intelligence, and machine learning, the company says it will be the first provider in Canada to give patients full control of their fertility journey through advanced technology tools.
According to Pollin, patients will be able to manage their journey, communicate with their care navigator, access results and receive information on demand.
“Global fertility success rates are incredibly low and accepted as industry standard,” said Melody Adhami, president and CEO at Pollin Fertility.
“Those struggling with infertility deserve better. We can do better. Every business across the globe is innovating through technology and fertility treatments should be no different.
“Pollin will offer patients the warm, welcoming environment patients crave while simultaneously delivering in-house technology that is poised to deliver the best success rates in the industry.”
Adhami, a fertility patient herself, and Dr Garbedian together share a vision of a fertility experience that truly works for patients.
Garbedian, said: “Patients are at the heart of everything we do. We are committed to providing our patients with a compassionate and supportive fertility journey along with the most advanced fertility treatments available.”
The investment, led by Osmington Inc, is hoped to help the company become major player in the reproductive healthcare space and optimise success rates.
Lawrence Zucker, CEO of Osmington, said: “We are proud to invest in a team who have a track record of success and diverse skill sets that will deliver positive outcomes in fertility.
“Pollin is tackling one of the most rapidly growing challenges in the healthcare space and we are pleased to be part of the team that is going to change fertility care.”
Pollin will officially open on October 16 in the Yonge and Eglinton district, Toronto.
Diagnosis
Lung cancer drug shows breast cancer potential
Ovarian cancer cells quickly activate survival responses after PARP inhibitor treatment, and a lung cancer drug could help block this, research suggests.
PARP inhibitors are a common treatment for ovarian cancer, particularly in tumours with faulty DNA repair. They stop cancer cells fixing DNA damage, which leads to cell death, but many tumours later stop responding.
Researchers identified a way cancer cells may survive PARP inhibitor treatment from the outset, pointing to a potential way to block that response. A Mayo Clinic team found ovarian cancer cells rapidly switch on a pro-survival programme after exposure to PARP inhibitors. A key driver is FRA1, a transcription factor (a protein that turns genes on and off) that helps cancer cells adapt and avoid death.
The team then tested whether brigatinib, a drug approved for certain lung cancers, could block this response and boost the effect of PARP inhibitors. Brigatinib was chosen because it inhibits multiple signalling pathways involved in cancer cell survival.
In laboratory studies, combining brigatinib with a PARP inhibitor was more effective than either treatment alone. Notably, the effect was seen in cancer cells but not normal cells, suggesting a more targeted approach.
Brigatinib also appeared to act in an unexpected way. Rather than working through the usual DNA repair routes, it shut down two signalling molecules, FAK and EPHA2, that aggressive ovarian cancer cells rely on. FAK and EPHA2 are proteins that relay survival signals inside cells. Blocking both at once weakened the cells’ ability to adapt and resist treatment, making them more vulnerable to PARP inhibitors.
Tumours with higher levels of FAK and EPHA2 responded better to the drug combination. Other data link high levels of these molecules to more aggressive disease, pointing to potential benefit in harder-to-treat cases.
Arun Kanakkanthara, an oncology investigator at Mayo Clinic and a senior author of the study, said: “This work shows that drug resistance does not always emerge slowly over time; cancer cells can activate survival programmes very early after treatment begins.”
John Weroha, a medical oncologist at Mayo Clinic and a senior author of the study, said: “From a clinical perspective, resistance remains one of the biggest challenges in treating ovarian cancer. By combining mechanistic insights from Dr Kanakkanthara’s laboratory with my clinical experience, this preclinical work supports the strategy of targeting resistance early, before it has a chance to take hold. This strategy could improve patient outcomes.”
Insight
Higher nighttime temps linked to increased risk of autism diagnosis in children – study
Entrepreneur
Kindbody unveils next-gen fertility platform
-
Insight4 weeks agoDesigner perfumes recalled over banned chemical posing fertility risk
-
Insight2 weeks agoParents sue IVF clinic after delivering someone else’s baby
-
Insight3 weeks agoWomen’s health could unlock US$100bn by 2030
-
Wellness4 weeks agoChina’s birth rate hits record low despite government fertility efforts
-
Menopause3 weeks agoHRT linked to greater weight loss on tirzepatide
-
Entrepreneur6 days agoUS startup builds wearable hormone tracker
-
Menopause2 weeks agoFlo Health and Mayo Clinic publish global perimenopause awareness study
-
News4 weeks agoVerdane invest in Clue to accelerate the future of women’s health







2 Comments